Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
PRNewswire - December 4, 2001
Isoniazid is used frequently and extensively in foreign countries with low-income populations due to the relative inexpensiveness compared to other therapeutic drugs.
Lannett is currently working on several new prescription product offerings. The company's current and pipeline products serve a diverse range of medical treatments, including Attention-Deficit-Hyperactivity-Disorder, Pain Management, Irritable Bowel Syndrome, Allergies, Weight Management, and Epilepsy. Lannett has approximately 95 employees and manufactures both prescription and over-the-counter generic drugs.
This press release contains certain statements of a forward-looking nature relating to future events or future business performance. Any such statements that refer to Lannett's estimated or anticipated future financial results, future inventory levels, future competition or pricing, future levels of operating expenses, product development efforts or performance, or other non- historical facts are forward-looking and reflect Lannett's current perspective of existing trends and information. These statements involve risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward- looking statements. Such risks and uncertainties include, among others, the uncertainty that actual results may differ materially from the preliminary results described in this press release, rates of sale of customer inventories, the success of Lannett's product development activities and the timeliness with which regulatory authorizations and product roll-out may be achieved, market acceptance of Lannett's products and the impact of competitive products and pricing, the availability on commercially reasonable terms of raw materials and other third party sourced products, successful compliance with extensive, costly, complex and evolving governmental regulations and restrictions, exposure to product liability and other lawsuits and contingencies, and other risks and uncertainties detailed in Lannett's most recent filings with the Securities and Exchange Commission, including but not limited to: Lannett's Annual Report and Form 10-K for the year ended June 30, 2001.
The Company's common stock trades in the over-the-counter market through the use of the inter-dealer "pink sheets," published by the National Quotations Bureau, Inc. under the symbol ("LANN"). For more information please call Larry Dalesandro at 215-333-9000.
SOURCE Lannett Company, Inc.
011204
PR011206
Copyright © 2001 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.PRNewswire.com.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .